Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Hypermutation of the inactive X chromosome is a frequent event in cancer.

Jäger N, Schlesner M, Jones DT, Raffel S, Mallm JP, Junge KM, Weichenhan D, Bauer T, Ishaque N, Kool M, Northcott PA, Korshunov A, Drews RM, Koster J, Versteeg R, Richter J, Hummel M, Mack SC, Taylor MD, Witt H, Swartman B, Schulte-Bockholt D, Sultan M, Yaspo ML, Lehrach H, Hutter B, Brors B, Wolf S, Plass C, Siebert R, Trumpp A, Rippe K, Lehmann I, Lichter P, Pfister SM, Eils R.

Cell. 2013 Oct 24;155(3):567-81. doi: 10.1016/j.cell.2013.09.042. Epub 2013 Oct 17.

2.

Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.

Hahm C, Huh HJ, Mun YC, Seong CM, Chung WS, Huh J.

Int J Lab Hematol. 2015 Apr;37(2):181-9. doi: 10.1111/ijlh.12257. Epub 2014 May 21.

PMID:
24845343
3.

Random replication of the inactive X chromosome.

Koren A, McCarroll SA.

Genome Res. 2014 Jan;24(1):64-9. doi: 10.1101/gr.161828.113. Epub 2013 Sep 24.

4.

The idic(X)(q13) in myeloid malignancies: breakpoint clustering in segmental duplications and association with TET2 mutations.

Paulsson K, Haferlach C, Fonatsch C, Hagemeijer A, Andersen MK, Slovak ML, Johansson B; MDS Foundation.

Hum Mol Genet. 2010 Apr 15;19(8):1507-14. doi: 10.1093/hmg/ddq024. Epub 2010 Jan 21.

PMID:
20093295
5.

[Analysis of the parental origin of de novo MECP2 mutations and X chromosome inactivation in fifteen sporadic cases with Rett syndrome].

Zhu XW, Pan H, Li MR, Bao XH, Zhang JJ, Wu XR.

Zhonghua Er Ke Za Zhi. 2009 Aug;47(8):565-9. Chinese.

PMID:
19951486
6.

[Cytogenetic characteristics of hematopoietic and stromal progenitor cells in myelodysplastic syndrome].

Pimenova MA, Parovichnikova EN, Kokhno AV, Domracheva EV, Manakova TE, Mal'tseva IuS, Konnova ML, Shishigina LA, Savchenko VG.

Ter Arkh. 2013;85(7):34-42. Russian.

PMID:
24137945
7.

Genomic landscape of CD34+ hematopoietic cells in myelodysplastic syndrome and gene mutation profiles as prognostic markers.

Xu L, Gu ZH, Li Y, Zhang JL, Chang CK, Pan CM, Shi JY, Shen Y, Chen B, Wang YY, Jiang L, Lu J, Xu X, Tan JL, Chen Y, Wang SY, Li X, Chen Z, Chen SJ.

Proc Natl Acad Sci U S A. 2014 Jun 10;111(23):8589-94. doi: 10.1073/pnas.1407688111. Epub 2014 May 21.

8.

Clonality studies and N-ras and p53 mutation analysis of hematopoietic cells in Fanconi anemia.

Venkatraj VS, Gaidano G, Auerbach AD.

Leukemia. 1994 Aug;8(8):1354-8.

PMID:
8057673
9.

Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes.

Fernandez-Mercado M, Burns A, Pellagatti A, Giagounidis A, Germing U, Agirre X, Prosper F, Aul C, Killick S, Wainscoat JS, Schuh A, Boultwood J.

Haematologica. 2013 Dec;98(12):1856-64. doi: 10.3324/haematol.2013.086686. Epub 2013 Jul 5.

10.

Analysis of mitochondrial DNA in 104 patients with myelodysplastic syndromes.

Wulfert M, Küpper AC, Tapprich C, Bottomley SS, Bowen D, Germing U, Haas R, Gattermann N.

Exp Hematol. 2008 May;36(5):577-86. doi: 10.1016/j.exphem.2008.01.004.

PMID:
18439489
11.

Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes.

Svobodova K, Zemanova Z, Lhotska H, Novakova M, Podskalska L, Belickova M, Brezinova J, Sarova I, Izakova S, Lizcova L, Berkova A, Siskova M, Jonasova A, Cermak J, Michalova K.

Leuk Res. 2016 Mar;42:7-12. doi: 10.1016/j.leukres.2016.01.009. Epub 2016 Jan 24.

PMID:
26851439
12.

The natural somatic mutation frequency and human carcinogenesis.

Simpson AJ.

Adv Cancer Res. 1997;71:209-40. Review.

PMID:
9111867
13.

Primitive hematopoietic stem cells shows a polyclonal pattern in myelodysplastic syndromes.

Guidetti F, Grazioli S, Capelli F, Marini C, Gallicchio M, De Micheli D, Castello L, Sainaghi PP, Fra GP, Saglio G, Avanzi GC.

Haematologica. 2004 Jan;89(1):21-8.

14.
15.

The small population of PIG-A mutant cells in myelodysplastic syndromes do not arise from multipotent hematopoietic stem cells.

Pu JJ, Hu R, Mukhina GL, Carraway HE, McDevitt MA, Brodsky RA.

Haematologica. 2012 Aug;97(8):1225-33. doi: 10.3324/haematol.2011.048215. Epub 2012 Feb 7.

16.

Recurrent Abnormal Clones in Myelodysplastic Syndrome Marrow Originate from Cells at a Pluripotent Stem Level and Maintain Their Early Differentiation Potency.

Qi H, Qingxia Z, Xiao L, Lingyun W, Feng X, Zheng Z, Chunkang C.

Cancer Invest. 2015;33(8):369-77. doi: 10.3109/07357907.2015.1044665. Epub 2015 Jul 2.

PMID:
26135215
17.

Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.

Lose F, Duffy DL, Kay GF, Kedda MA, Spurdle AB; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer; Australian Ovarian Cancer Study Management Group.

J Natl Cancer Inst. 2008 Nov 5;100(21):1519-29. doi: 10.1093/jnci/djn345. Epub 2008 Oct 28.

PMID:
18957670
18.

Characterization of chromosome arm 20q abnormalities in myeloid malignancies using genome-wide single nucleotide polymorphism array analysis.

Huh J, Tiu RV, Gondek LP, O'Keefe CL, Jasek M, Makishima H, Jankowska AM, Jiang Y, Verma A, Theil KS, McDevitt MA, Maciejewski JP.

Genes Chromosomes Cancer. 2010 Apr;49(4):390-9. doi: 10.1002/gcc.20748.

PMID:
20095039
19.

Characterization of loss-of-inactive X in Klinefelter syndrome and female-derived cancer cells.

Kawakami T, Zhang C, Taniguchi T, Kim CJ, Okada Y, Sugihara H, Hattori T, Reeve AE, Ogawa O, Okamoto K.

Oncogene. 2004 Aug 12;23(36):6163-9.

PMID:
15195139
20.

Mutations in the p53 gene in myelodysplastic syndromes.

Jonveaux P, Fenaux P, Quiquandon I, Pignon JM, Laï JL, Loucheux-Lefebvre MH, Goossens M, Bauters F, Berger R.

Oncogene. 1991 Dec;6(12):2243-7.

PMID:
1766671

Supplemental Content

Support Center